Alpha memo: urolithin / mitochondrial bounded update

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either (a) reframe as a genuine cross-compound/cross-tissue contrast (UroA in cardiac aging/HF vs. mUroA in D-gal-induced neuroinflammation) and provide an actual mechanistic or methodological reason the signal may not transfer, or (b) replace one receipt with a study that genuinely produces a null, conflicting, or boundary-demonstrating result on urolithin/mitochondrial endpoints.
2. Resolve the fabricated 'non-transfer' claim: if both receipts are positive, the honest alpha is a convergence signal within a defined class, not a translation boundary.
3. Disclose that Receipt 1 is a non-peer-reviewed preprint and explain how that affects the weight of the comparison.
4. Provide an explicit axis-by-axis contrast table (compound, species, model, dose, duration, tissue, endpoint, direction of effect) so the boundary claim — if retained — is falsifiable rather than rhetorical.

Major issues

• The central 'alpha' claim is incoherent: Receipt 1 is framed as positive (cardioprotection/mitochondrial quality in aging and heart failure) while Receipt 2 is also positive (cognitive improvement, reduced oxidative damage, NLRP3 inhibition in aging mice), yet the memo asserts Receipt 1 'does not automatically transfer to' Receipt 2 and frames the signal as a 'translation boundary.' No contrast, conflict, or null finding is presented — both receipts support a mitochondrial/aging benefit of urolithin-class compounds. The 'boundary' claim is fabricated rather than receipt-grounded.
• Title/source alignment is broken in a more subtle way: Receipt 1 is a bioRxiv preprint on cardiac endpoints and heart failure; Receipt 2 is on methylated urolithin A in a D-galactose mouse model with cognitive/NLRP3 endpoints. The memo treats these as a 'same anchor' pair, but the compound (UroA vs. mUroA), organ system (heart vs. brain), and model (natural aging/HF vs. D-gal-induced aging) all differ, and the memo does not actually adjudicate transfer across these axes — it just asserts a boundary.
• The 'bounded contrast' section degenerates into tautology ('Receipt 1 axes: endpoint not explicit in title'), which is not a falsifiable contrast statement.
• Receipt 1 is a bioRxiv preprint (not peer-reviewed); Receipt 2 is a peer-reviewed Neuropharmacology paper. Treating these as symmetrically weighted 'receipts' without flagging the asymmetry is a source-quality omission.
• The synthesis reads as meta-commentary on what an alpha memo should look like rather than an actual evidence-grounded analysis of the two papers.

Minor issues

• The abstract/synthesis repeats the same sentence almost verbatim, reducing information density.
• 'Why this is surprising' offers no concrete mechanistic or empirical reason for surprise — both papers report positive urolithin-family mitochondrial findings.
• No quantitative effect sizes, doses, or model details from Receipt 2 are integrated; only the abstract excerpt is paraphrased.

Reviewer note

The memo presents itself as a 'bounded translation boundary' alpha, but the two cited receipts both report positive urolithin-family mitochondrial findings in aging models — there is no conflict, null, or boundary condition in the source material. The central claim that Receipt 1 'does not automatically transfer' to Receipt 2 is therefore fabricated rather than receipt-grounded. Both compounds (UroA vs. mUroA), tissues (heart vs. brain), and models (natural aging/HF vs. D-gal-induced) differ, which could justify a cross-setting comparison, but the memo never actually compares them along these axes — it just asserts a boundary. Receipt 1 is also a non-peer-reviewed preprint, which should be flagged. Recommendation: reject; the memo needs a scope reset and either a genuinely conflicting receipt or an honest reframing as a cross-tissue/cross-compound convergence signal.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis